metaboliqWhat Mounjaro is
Mounjaro is tirzepatide, launched in India by Eli Lilly after approval from the national regulator. Cipla sells the same molecule under the name Yurpeak.
It acts on two gut hormone receptors, GIP and GLP-1, which is why it is sometimes called a dual agonist. Together they slow how fast the stomach empties, increase fullness, reduce appetite and help the body release insulin when blood sugar rises.
Who it is approved for
In India it is approved for adults with type 2 diabetes, alongside diet and activity. It is also approved for chronic weight management in adults with obesity, or with overweight and a related condition such as raised blood pressure or prediabetes.
The regulator has asked states to keep these products to their approved uses and labelling. Anything outside that is a clinical judgement a doctor has to make and explain.
What the trials found
In SURMOUNT-1, adults without diabetes on the three strengths reduced body weight by an average of 15.0%, 19.5% and 20.9% over 72 weeks, against 3.1% on placebo.
Real-world results are usually smaller and slower than trial averages. In the first Indian cohort study, 150 people at one hospital had a median reduction of 8.2% at about six months.
Who decides, and how it is started
It is prescription-only in India, and a doctor decides whether it fits you after reading your history, your blood tests and anything else you take.
It is started at a low strength and stepped up every four weeks or so, because stepping up slowly is what keeps the stomach side effects manageable.
Sold outside an authorised pharmacy, a pen can be fake, wrongly stored or the wrong strength; the regulator has asked states to keep these products to authorised channels and their approved uses.
Sources: [7]
What it costs in India
Reported figures put tirzepatide pens in India at about Rs 13,125 to Rs 25,781 a month, rising with the strength. These are reported market prices, they change, and a pharmacist quotes the current MRP.
Metaboliq does not sell it. The cost that matters is the whole plan: the tests, the doctor, the follow-up and the habits that last after it.
Sources: [6]
Why muscle matters
Body weight falls as fat and as lean tissue together. In the STEP 1 body-composition substudy, roughly 40% of the total lost was lean mass.
Muscle is what keeps blood sugar handled well, keeps you strong as you age and keeps your daily energy use up. So the plan around any treatment protects it: protein at every meal, strength training two or three times a week, and body composition measured rather than the scale alone.
Sources: [8]
What happens when it is stopped
These work while they are taken. One year after semaglutide was stopped in the STEP 1 extension, people had regained about two-thirds of what they had lost; in SURMOUNT-4, people switched from tirzepatide to placebo regained about 14% of body weight.
That is why the habits built alongside treatment, and a plan for maintenance, matter as much as the treatment itself.
Side effects
Common, and usually easing with time
- Nausea, most often in the first weeks and after each step up.
- Diarrhoea or constipation.
- Vomiting, indigestion, burping and bloating.
- Feeling full early, and less appetite.
- Tiredness, and headache.
Serious, and rare
- Pancreatitis: severe, lasting pain in the upper abdomen that may spread to the back, with or without vomiting.
- Gallbladder problems, including gallstones, which are more likely when body weight falls quickly.
- Dehydration from vomiting or diarrhoea, which can strain the kidneys.
- Low blood sugar, mainly when it is combined with insulin or a sulfonylurea.
- Allergic reactions, rare but serious.
- A history of medullary thyroid cancer or MEN 2 in you or your family is a reason it is not used.
Stop and get medical help at once for severe abdominal pain, repeated vomiting, signs of an allergic reaction, or sudden changes in vision. Tell the doctor about pregnancy plans first: these are not used in pregnancy.